hpk-1-in-4

HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.

HPK1-IN-47, a PROTAC HPK1 degrader (DC 50: 23 nM in PBMCs), serves as a precursor for the synthesis of compounds like PROTAC HPK1 Degrader-2. It is utilized in research focused on diseases mediated by HPK1, including cancer.

HPK1-IN-43 (compound 9f) is an HPK1 kinase inhibitor with an IC50 value of 0.32 nM. It inhibits the phosphorylation of the downstream protein SLP-76 in PBMC cells and enhances the secretion of interleukin 2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 is applicable to cancer research.

HPK1-IN-45 (Compound 3) is an HPK1 inhibitor with an IC50 of 0.3 nM. It hinders the phosphorylation of SLP-76 (IC50= 57.52 nM) and the release of IL-2 (IC50= 38 nM). This compound is applicable in cancer research.

HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 with an IC50 of 0.1 nM (40 μM ATP).

HPK1-IN-48 (compound 14g) is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), with an IC50 value of 0.15 nM. Additionally, HPK1-IN-48 significantly inhibits the phosphorylation of SLP76, demonstrating an IC50 of 27.92 nM.

HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].

HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].

HPK1-IN-49 (Compound I-4) serves as an inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), exhibiting an IC50 value greater than 100 nM.

HPK1-IN-2 (Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2) is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1; IC50<0.05 μΜ). It also inhibits Lck (0.05 μΜinase activities with antitumor activity.